Terms: = Ovarian cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
85 results:
1. Mass Spectrometry-Based Proteomics of Epithelial ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
2. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
Sánchez-Fdez A; Matilla-Almazán S; Montero JC; Del Carmen S; Abad M; García-Alonso S; Bhattacharya S; Calar K; de la Puente P; Ocaña A; Pandiella A; Esparís-Ogando A
Clin Transl Med; 2023 Apr; 13(4):e1217. PubMed ID: 37029785
[TBL] [Abstract] [Full Text] [Related]
3. Jinfeng pills ameliorate premature ovarian insufficiency induced by cyclophosphamide in rats and correlate to modulating IL-17A/IL-6 axis and MEK/ERK signals.
Hu YY; Zhong RH; Guo XJ; Li GT; Zhou JY; Yang WJ; Ren BT; Zhu Y
J Ethnopharmacol; 2023 May; 307():116242. PubMed ID: 36775079
[TBL] [Abstract] [Full Text] [Related]
4. Increased endogenous PKG I activity attenuates EGF-induced proliferation and migration of epithelial ovarian cancer via the MAPK/ERK pathway.
Lan T; Li Y; Wang Y; Wang ZC; Mu CY; Tao AB; Gong JL; Zhou Y; Xu H; Li SB; Gu B; Ma P; Luo L
Cell Death Dis; 2023 Jan; 14(1):39. PubMed ID: 36653376
[TBL] [Abstract] [Full Text] [Related]
5. Role of RAS signaling in ovarian cancer.
Therachiyil L; Anand A; Azmi A; Bhat A; Korashy HM; Uddin S
F1000Res; 2022; 11():1253. PubMed ID: 36451660
[TBL] [Abstract] [Full Text] [Related]
6. NOTCH Signaling Limits the Response of Low-Grade Serous ovarian cancers to MEK Inhibition.
Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
[TBL] [Abstract] [Full Text] [Related]
7. Protein expression profiling identifies a prognostic model for ovarian cancer.
Xiong L; Tan J; Feng Y; Wang D; Liu X; Feng Y; Li S
BMC Womens Health; 2022 Jul; 22(1):292. PubMed ID: 35840928
[TBL] [Abstract] [Full Text] [Related]
8. Rare ovarian cancer's First Positive Trial.
Cancer Discov; 2022 Apr; 12(4):879. PubMed ID: 35373274
[TBL] [Abstract] [Full Text] [Related]
9. Knockdown of growth factor receptor bound protein 7 suppresses angiogenesis by inhibiting the secretion of vascular endothelial growth factor A in ovarian cancer cells.
Xu Q; Liu Z; Zhu ZQ; Fan Y; Chen R; Xie XH; Cheng M
Bioengineered; 2021 Dec; 12(2):12179-12190. PubMed ID: 34783299
[TBL] [Abstract] [Full Text] [Related]
10. Flavonoids Restore Platinum Drug Sensitivity to ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract] [Full Text] [Related]
11. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ; Grisham RN; Banerjee S; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Drill E; Cibula D; Moore KN; Christy-Bittel J; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Boyd AP; Kristensen G; Clamp A; Ray-Coquard I; Vergote I
J Clin Oncol; 2020 Nov; 38(32):3753-3762. PubMed ID: 32822286
[TBL] [Abstract] [Full Text] [Related]
12. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract] [Full Text] [Related]
13. Molecular Profiles of Mixed Endometrial Carcinoma.
Matrai C; Motanagh S; Mirabelli S; Ma L; He B; Chapman-Davis E; Kurtis B; Elemento O; Mosquera JM; Ellenson LH
Am J Surg Pathol; 2020 Aug; 44(8):1104-1111. PubMed ID: 32604171
[TBL] [Abstract] [Full Text] [Related]
14. Dietary compound glycyrrhetinic acid suppresses tumor angiogenesis and growth by modulating antiangiogenic and proapoptotic pathways in vitro and in vivo.
Li J; Tang F; Li R; Chen Z; Lee SM; Fu C; Zhang J; Leung GP
J Nutr Biochem; 2020 Mar; 77():108268. PubMed ID: 31830590
[TBL] [Abstract] [Full Text] [Related]
15. Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways.
Zhang X; Hou G; Liu A; Xu H; Guan Y; Wu Y; Deng J; Cao X
Cell Death Dis; 2019 Oct; 10(10):770. PubMed ID: 31601793
[TBL] [Abstract] [Full Text] [Related]
16. Zamzam water protects cancer cells from chemotherapy-induced apoptosis via mitogen-activated protein kinase-dependent pathway.
Siraj AK; Begum R; Melosantos R; Albalawy W; Abboud J; Siraj N; Al-Kuraya KS
Biomed Pharmacother; 2019 Oct; 118():109376. PubMed ID: 31545262
[TBL] [Abstract] [Full Text] [Related]
17. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract] [Full Text] [Related]
18. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Booth L; Roberts J; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
[TBL] [Abstract] [Full Text] [Related]
19. Autotaxin exacerbates tumor progression by enhancing mek1 and overriding the function of miR-489-3p.
Kuppa SS; Jia W; Liu S; Nguyen H; Smyth SS; Mills GB; Dobbin KK; Hardman WJ; Murph MM
Cancer Lett; 2018 Sep; 432():84-92. PubMed ID: 29859298
[TBL] [Abstract] [Full Text] [Related]
20. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract] [Full Text] [Related]
[Next]
